Concepts (88)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Brain Neoplasms | 9 | 2018 | 88 | 2.920 |
Why?
|
| Income | 3 | 2017 | 77 | 1.590 |
Why?
|
| Astrocytoma | 4 | 2016 | 20 | 1.280 |
Why?
|
| Oligodendroglioma | 3 | 2016 | 6 | 1.170 |
Why?
|
| Insurance Coverage | 2 | 2017 | 16 | 1.100 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2018 | 177 | 1.030 |
Why?
|
| Medically Uninsured | 2 | 2017 | 13 | 0.710 |
Why?
|
| Radiation Injuries | 3 | 2017 | 32 | 0.680 |
Why?
|
| Glioma | 3 | 2014 | 20 | 0.670 |
Why?
|
| Gliosarcoma | 2 | 2017 | 2 | 0.670 |
Why?
|
| Mouth Neoplasms | 1 | 2018 | 21 | 0.590 |
Why?
|
| Pharyngeal Neoplasms | 1 | 2017 | 4 | 0.580 |
Why?
|
| Chemoradiotherapy, Adjuvant | 1 | 2017 | 17 | 0.570 |
Why?
|
| Cranial Irradiation | 2 | 2014 | 13 | 0.550 |
Why?
|
| Insurance, Health | 1 | 2016 | 23 | 0.540 |
Why?
|
| Combined Modality Therapy | 2 | 2016 | 307 | 0.520 |
Why?
|
| Healthcare Disparities | 1 | 2016 | 86 | 0.510 |
Why?
|
| Young Adult | 7 | 2018 | 2069 | 0.480 |
Why?
|
| Adolescent | 5 | 2018 | 2307 | 0.440 |
Why?
|
| Aged | 11 | 2019 | 9262 | 0.430 |
Why?
|
| Aged, 80 and over | 6 | 2018 | 4853 | 0.420 |
Why?
|
| Radiotherapy, Adjuvant | 3 | 2018 | 52 | 0.410 |
Why?
|
| Kaplan-Meier Estimate | 3 | 2016 | 179 | 0.390 |
Why?
|
| Middle Aged | 10 | 2018 | 9254 | 0.380 |
Why?
|
| Male | 14 | 2019 | 15273 | 0.370 |
Why?
|
| Adult | 8 | 2018 | 8097 | 0.360 |
Why?
|
| Female | 13 | 2019 | 15708 | 0.350 |
Why?
|
| Prognosis | 5 | 2019 | 825 | 0.310 |
Why?
|
| Humans | 16 | 2019 | 28408 | 0.290 |
Why?
|
| Medicaid | 2 | 2017 | 38 | 0.270 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 352 | 0.260 |
Why?
|
| Chemotherapy, Adjuvant | 2 | 2016 | 81 | 0.260 |
Why?
|
| Medicare | 2 | 2017 | 121 | 0.260 |
Why?
|
| Regression Analysis | 2 | 2016 | 266 | 0.250 |
Why?
|
| Survival Rate | 4 | 2019 | 356 | 0.230 |
Why?
|
| Age Factors | 2 | 2016 | 781 | 0.220 |
Why?
|
| Neural Stem Cells | 2 | 2014 | 13 | 0.210 |
Why?
|
| United States | 3 | 2019 | 2197 | 0.200 |
Why?
|
| Databases, Factual | 2 | 2019 | 358 | 0.160 |
Why?
|
| Melanoma | 1 | 2019 | 60 | 0.150 |
Why?
|
| Paranasal Sinus Neoplasms | 1 | 2019 | 63 | 0.150 |
Why?
|
| Propensity Score | 1 | 2018 | 36 | 0.150 |
Why?
|
| Lymphocytes | 1 | 2018 | 63 | 0.150 |
Why?
|
| Radiosurgery | 1 | 2018 | 38 | 0.150 |
Why?
|
| Private Sector | 1 | 2017 | 2 | 0.140 |
Why?
|
| Retrospective Studies | 5 | 2019 | 3609 | 0.140 |
Why?
|
| Neutrophils | 1 | 2018 | 110 | 0.140 |
Why?
|
| Pituitary Neoplasms | 1 | 2017 | 16 | 0.140 |
Why?
|
| Neoplasm Grading | 2 | 2014 | 52 | 0.140 |
Why?
|
| Social Class | 1 | 2017 | 66 | 0.140 |
Why?
|
| Frail Elderly | 1 | 2017 | 53 | 0.140 |
Why?
|
| Survival Analysis | 1 | 2017 | 267 | 0.140 |
Why?
|
| Karnofsky Performance Status | 1 | 2016 | 2 | 0.130 |
Why?
|
| Paranasal Sinuses | 1 | 2017 | 62 | 0.130 |
Why?
|
| Radiotherapy, Intensity-Modulated | 2 | 2014 | 38 | 0.130 |
Why?
|
| Multivariate Analysis | 1 | 2016 | 331 | 0.120 |
Why?
|
| Neoplastic Stem Cells | 1 | 2014 | 7 | 0.120 |
Why?
|
| Sinusitis | 1 | 2017 | 161 | 0.120 |
Why?
|
| Standard of Care | 1 | 2014 | 13 | 0.110 |
Why?
|
| Parotid Gland | 1 | 2014 | 18 | 0.110 |
Why?
|
| Brain Injuries | 1 | 2014 | 36 | 0.110 |
Why?
|
| Lymphatic Metastasis | 1 | 2014 | 90 | 0.110 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2014 | 206 | 0.110 |
Why?
|
| Head and Neck Neoplasms | 1 | 2014 | 151 | 0.100 |
Why?
|
| Limbic System | 1 | 2011 | 8 | 0.090 |
Why?
|
| Pluripotent Stem Cells | 1 | 2011 | 7 | 0.090 |
Why?
|
| Hippocampus | 1 | 2011 | 278 | 0.080 |
Why?
|
| Magnetic Resonance Imaging | 4 | 2017 | 1143 | 0.080 |
Why?
|
| Brain | 1 | 2017 | 1663 | 0.070 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 1858 | 0.050 |
Why?
|
| Nasal Mucosa | 1 | 2019 | 13 | 0.040 |
Why?
|
| Leukocyte Count | 1 | 2018 | 66 | 0.040 |
Why?
|
| Growth Hormone-Secreting Pituitary Adenoma | 1 | 2017 | 3 | 0.040 |
Why?
|
| Facial Pain | 1 | 2017 | 7 | 0.040 |
Why?
|
| Neoplasm Staging | 1 | 2019 | 371 | 0.040 |
Why?
|
| Vision Disorders | 1 | 2017 | 22 | 0.040 |
Why?
|
| Headache | 1 | 2017 | 34 | 0.040 |
Why?
|
| Eosinophilia | 1 | 2017 | 37 | 0.030 |
Why?
|
| Nasal Polyps | 1 | 2017 | 54 | 0.030 |
Why?
|
| Diagnosis, Differential | 1 | 2017 | 372 | 0.030 |
Why?
|
| Chronic Disease | 1 | 2017 | 441 | 0.030 |
Why?
|
| Rhinitis | 1 | 2017 | 143 | 0.030 |
Why?
|
| Severity of Illness Index | 1 | 2017 | 986 | 0.030 |
Why?
|
| Brain Edema | 1 | 2011 | 18 | 0.020 |
Why?
|
| Tumor Burden | 1 | 2011 | 28 | 0.020 |
Why?
|
| Radiotherapy Dosage | 1 | 2011 | 117 | 0.020 |
Why?
|
| Feasibility Studies | 1 | 2011 | 231 | 0.020 |
Why?
|
| Child | 1 | 2014 | 1421 | 0.020 |
Why?
|